DAX25.283 ±-0,0%Est506.136 -0,4%MSCI World4.343 -0,1%Top 10 Crypto8,4700 -1,5%Nas22.692 -0,8%Bitcoin55.788 -2,4%Euro1,1816 +0,2%Öl72,60 +2,4%Gold5.248 +1,3%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 Deutsche Telekom 555750 Rheinmetall 703000 Siemens Energy ENER6Y Novo Nordisk A3EU6F SAP 716460 freenet A0Z2ZZ BASF BASF11 Allianz 840400 Lufthansa 823212 DroneShield A2DMAA Bayer BAY001 Netflix 552484 Microsoft 870747 Infineon 623100
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX stabil -- Wall Street tiefrot -- Netflix steigt aus Warner-Bieterkampf aus -- BASF für 2026 vorsichtig -- Delivery Hero: Umsatz enttäuscht -- 1&1, Dell, Block, AIXTRON im Fokus
Top News
Sanofi-Aktie im Plus: Regeneron und Sanofi ergattern Empfehlung für erweiterte Dupixent-Zulassung Sanofi-Aktie im Plus: Regeneron und Sanofi ergattern Empfehlung für erweiterte Dupixent-Zulassung
Tesla-Aktie etwas tiefer: Elon Musk kündigt Robotaxis und Roboter-Offensive in Europa an Tesla-Aktie etwas tiefer: Elon Musk kündigt Robotaxis und Roboter-Offensive in Europa an
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Vanda Pharmaceuticals Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
7,25 EUR ±0,00 EUR ±0,00 %
STU
8,62 USD +0,01 USD +0,12 %
BTT
Vanda Pharmaceuticals jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.414,16 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA0JJT3

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS9216591084

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolVNDA

Vanda Pharmaceuticals Aktien News

DatumMeistgelesen
BenzingaVanda Pharmaceuticals Breaks Through With FDA Approval, Decision Date For Skin Drug
BenzingaImmunityBio Posts Upbeat Q4 Earnings, Joins Arcellx, Vanda Pharmaceuticals And Other Big Stocks Moving Higher On Monday
BenzingaVanda Pharmaceuticals FDA Approval Dawns A New Era For Bipolar And Schizophrenia Treatment
Wer­bungVanda Pharmaceuticals-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
BenzingaWhy Vanda Pharmaceuticals Shares Are Trading Higher By Around 33%; Here Are 20 Stocks Moving Premarket
ZacksVanda Pharmaceuticals (VNDA) Reports Q4 Loss, Lags Revenue Estimates
PR NewswireVanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag Disorder
BenzingaWhat's Going On With Vanda Pharmaceuticals Stock Wednesday?
BenzingaWhy Vanda Pharmaceuticals Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
BenzingaVanda Pharmaceuticals, One Stop Systems And 3 Stocks To Watch Heading Into Wednesday
PR NewswireVanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness
PR NewswireVanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis
PR NewswireVanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference
PR NewswireFDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness
PR NewswireVanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness
PR NewswireVanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1 Induced Nausea and Vomiting
PR NewswireVanda Pharmaceuticals Announces Participation in the Stifel 2025 Healthcare Conference
ZacksVanda Pharmaceuticals (VNDA) Reports Q3 Loss, Misses Revenue Estimates
PR NewswireVanda Pharmaceuticals Reports Third Quarter 2025 Financial Results
PR NewswireVanda Pharmaceuticals to Announce Third Quarter 2025 Financial Results on October 29, 2025
PR NewswireMonumental Sports & Entertainment Taps D.C.'s Own Vanda Pharmaceuticals as Founding Partner to Help Drive the Creation of Brand-New Downtown Arena
PR NewswireVanda Pharmaceuticals announces the publication in PLOS One of an article titled "Melatonin agonist tasimelteon (HETLIOZ®) improves sleep in patients with primary insomnia: A multicenter, randomiz...
PR NewswireVanda Pharmaceuticals Announces Participation at September 2025 Investor Conferences
PR NewswireVanda Pharmaceuticals Announces FDA Granted Orphan Drug Designation for VGT-1849B, a Novel and Selective Candidate for the Treatment of Polycythemia Vera
ZacksVanda Pharmaceuticals (VNDA) Reports Q2 Loss, Misses Revenue Estimates
PR NewswireVanda Pharmaceuticals Reports Second Quarter 2025 Financial Results
PR NewswireVanda Pharmaceuticals to Announce Second Quarter 2025 Financial Results on July 31, 2025
PR NewswireVanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S
PR NewswireVanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual Meeting
PR NewswireVanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025
ZacksVanda Pharmaceuticals (VNDA) Reports Q1 Loss, Tops Revenue Estimates
PR NewswireVanda Pharmaceuticals Reports First Quarter 2025 Financial Results
PR NewswireVanda Announces Bysanti™ NDA Filing; FDA Decision Expected in Early 2026
PR NewswireVanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025
PR NewswireVanda Pharmaceuticals Announces Presentation at 2025 AAN Annual Meeting
BenzingaForecasting The Future: 5 Analyst Projections For Vanda Pharmaceuticals
PR NewswireVanda Pharmaceuticals Announces the Submission of an NDA to the FDA for Bysanti™ for the Treatments of Acute Bipolar I Disorder and Schizophrenia
PR NewswireVanda Pharmaceuticals announces the publication of an article titled "Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S"
PR NewswireVanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
PR NewswireVanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025
PR NewswireVanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist

Vanda Pharmaceuticals News

Vanda Pharmaceuticals News: auf dieser Seite finden Sie alle Vanda Pharmaceuticals News und Nachrichten zur Vanda Pharmaceuticals Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Vanda Pharmaceuticals News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Vanda Pharmaceuticals News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.